← Back to Search

Patient-Reported Outcomes Monitoring for Kidney Cancer Treatment Side Effects (PRO-VISION Trial)

N/A

Recruiting

Led By Tracy Rose

Research Sponsored by UNC Lineberger Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically confirmed renal cell carcinoma requiring treatment with VEGF TKI

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

PRO-VISION Trial Summary

This trial explores how collecting patient data directly can help manage side effects of oral chemo for mRCC. Patients will complete weekly surveys and be contacted when symptoms worsen. Through this trial, researchers hope to improve patient care.

Who is the study for?

This trial is for adults with renal cell carcinoma who need VEGF TKI treatment. They must be able to complete surveys in English or Spanish and have internet or phone access. Those unable to do the surveys are excluded.Check my eligibility

What is being tested?

The study tests if monitoring side effects through weekly patient-reported outcomes via survey can help manage symptoms from oral VEGFR TKI chemotherapies used in metastatic kidney cancer.See study design

What are the potential side effects?

There are no direct side effects from participating in the study itself, but it monitors common side effects of VEGFR TKIs like nausea and fatigue.

PRO-VISION Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My kidney cancer needs treatment targeting blood vessel growth.

PRO-VISION Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Relative dose intensity

Secondary outcome measures

Adherence to Patient Reported Outcome -based symptom

Dose interruption

Dose modifications

+10 more

PRO-VISION Trial Design

1Treatment groups

Experimental Treatment

Group I: Patient PerspectiveExperimental Treatment1 Intervention

Study participants will complete several questionnaires/assessments related to adverse events and quality of life.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor

351 Previous Clinical Trials

88,291 Total Patients Enrolled

Doris Duke Charitable FoundationOTHER

61 Previous Clinical Trials

260,044 Total Patients Enrolled

Tracy RosePrincipal InvestigatorUNC Lineberger Comprehensive Cancer Center

Media Library

Patient Perspective Clinical Trial Eligibility Overview. Trial Name: NCT05592665 — N/A

Kidney Cancer Research Study Groups: Patient Perspective

Kidney Cancer Clinical Trial 2023: Patient Perspective Highlights & Side Effects. Trial Name: NCT05592665 — N/A

Patient Perspective 2023 Treatment Timeline for Medical Study. Trial Name: NCT05592665 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there any capacity for additional participants in this research endeavor?

"As per clinicaltrials.gov, this study is currently enrolling eligible patients. It was originally posted on March 18th 2022 and has been amended as recently as October 19th 2022."

Answered by AI

What is the sample size of this clinical trial?

"Confirmed. The clinicaltrial.gov website indicates that this trial is actively recruiting participants, having been posted on March 18th 2022 and modified as recently as October 19th 2022. A total of 42 patients are being sourced from one location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology

2022. "PRO-VISION: Patient Reported Outcomes-Based Monitoring of VEGF-Inhibitor Side Effects in ONcology". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05592665.

All > Vision